Earnings History Data for Poseida Therapeutics (PSTX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Poseida Therapeutics

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	PM		PSTX	Poseida Therapeutics	258.00	0.21	-0.42	0.00	Poseida Therapeutics GAAP EPS of $0.21, revenue of $71.7M [11/8/2024 12:18 AM]	3.06	0.13 (4.61%)	3.22	0.29 (9.90%)	1.87 - 4.27	1,128,319	430,000	12,757
Poseida Therapeutics GAAP EPS of $0.21, revenue of $71.7M [11/8/2024 12:18 AM]
05-08-2024	AH		PSTX	Poseida Therapeutics	322.00	-0.32	-0.43	0.00	Poseida Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $26M beats by $10.58M [8/5/2024 5:32 PM]	3.12	0.10 (3.48%)	3.02	0.0 (0.00%)	1.83 - 4.27	512,270	600,000	57,590
Poseida Therapeutics files for mixed shelf offering of up to $300M [8/5/2024 4:43 PM] Poseida Therapeutics GAAP EPS of -$0.32 beats by $0.09, revenue of $26M beats by $10.58M [8/5/2024 5:32 PM]
07-03-2024	AH		PSTX	Poseida Therapeutics	333.00	-0.27	-0.36	0.00	Poseida Therapeutics GAAP EPS of -$0.27 beats by $0.12, revenue of $25M beats by $18.35M [3/7/2024 5:16 PM]	4.08	0.65 (18.80%)	3.55	0.12 (3.50%)	1.54 - 5.48	2,578,752	620,000	22,370
Poseida Therapeutics GAAP EPS of -$0.27 beats by $0.12, revenue of $25M beats by $18.35M [3/7/2024 5:16 PM]
08-08-2023	AH		PSTX	Poseida Therapeutics	141.00	-0.32	-0.53	0.00	Poseida Therapeutics GAAP EPS of -$0.32 beats by $0.21, revenue of $20.01M beats by $14.93M [8/8/2023 5:35 PM]	2.71	0.73 (37.12%)	2.01	0.03 (1.52%)	1.54 - 8.82	4,688,821	1,730,000	6,588
Poseida Therapeutics GAAP EPS of -$0.32 beats by $0.21, revenue of $20.01M beats by $14.93M [8/8/2023 5:35 PM]
09-05-2023	AH	4:05 PM ET (May 9)	PSTX	Poseida Therapeutics	284.00	-0.45	-0.40	0.00	Poseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34M [5/9/2023 5:55 PM]	3.40	0.0 (0.00%)	3.30	-0.10 (-2.94%)	1.82 - 8.82	432,470	500,000	2,125
Poseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34M [5/9/2023 5:55 PM]
10-11-2022	AH		PSTX	Poseida Therapeutics	371.00	0.92	-0.68	0.00	Poseida Therapeutics GAAP EPS of $0.92 beats by $1.57, revenue of $116.3M beats by $115.47M [11/10/2022 5:15 PM]	4.77	0.27 (6.00%)	4.67	0.17 (3.78%)	1.82 - 7.84	949,752	210,000	4,809
Poseida Therapeutics GAAP EPS of $0.92 beats by $1.57, revenue of $116.3M beats by $115.47M [11/10/2022 5:15 PM] Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 [Nov-10-22 04:05PM] Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates [Nov-10-22 06:45PM]
12-05-2022	AH	4:05 PM ET (May 12)	PSTX	Poseida Therapeutics	135.00	-0.93	-0.58	0.00	Poseida Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $1.44M beats by $0.61M [5/12/2022 4:58 PM]	2.17	0.30 (15.78%)	1.87	0.0 (0.00%)	1.83 - 11.10	244,569	360,000	2,225
Poseida Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $1.44M beats by $0.61M [5/12/2022 4:58 PM] Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 [May-12-22 04:05PM] Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates [May-12-22 06:05PM]
09-11-2021	AH	4:05 PM ET (Nov 9)	PSTX	Poseida Therapeutics	431.00	-0.68	-0.75	0.00	Poseida Therapeutics EPS beats by $0.07 [11/9/2021 4:58 PM]	7.02	0.26 (3.85%)	6.76	0.0 (0.00%)	6.20 - 13.98	215,425	150,000	341
Poseida Therapeutics EPS beats by $0.07 [11/9/2021 4:58 PM] Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 [Nov-09-21 04:05PM] Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting [Nov-09-21 08:05AM] Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know [Nov-08-21 10:46AM]
12-08-2021	AH		PSTX	Poseida Therapeutics, Inc.	538.00	-0.74	-0.64	0.00		8.87	0.09 (1.03%)	8.78	0.0 (0.00%)	7.63 - 13.98	93,174	90,000	2,427
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 [Aug-12-21 04:05PM]
11-05-2021	AH	4:05 PM ET (May 11)	PSTX	Poseida Therapeutics, Inc.	538.00	-0.62	-0.67	0.00	Poseida Therapeutics EPS beats by $0.05 [5/11/2021 4:41 PM]	8.46	-0.04 (-0.47%)	8.50	0.0 (0.00%)	7.63 - 17.62	169,330	130,000	288
Poseida Therapeutics EPS beats by $0.05 [5/11/2021 4:41 PM] Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 [May-11-21 04:05PM] Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting [May-11-21 08:00AM]
11-03-2021	AH		PSTX	Poseida Therapeutics, Inc.	544.63	-0.58	-0.69	0.00	Poseida Therapeutics EPS beats by $0.11 [3/11/2021 5:16 PM]	11.06	1.26 (12.86%)	9.95	0.15 (1.53%)	7.63 - 17.62	799,153	589,691	1,430
Poseida Therapeutics EPS beats by $0.11 [3/11/2021 5:16 PM] Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 [Mar-11-21 04:05PM]